MicroRNA-145 as one negative regulator of astrogliosis

Glia. 2015 Feb;63(2):194-205. doi: 10.1002/glia.22743. Epub 2014 Aug 20.

Abstract

Astrogliosis occurs at the lesion site within days to weeks after spinal cord injury (SCI) and involves the proliferation and hypertrophy of astrocytes, leading to glia scar formation. Changes in gene expression by deregulated microRNAs (miRNAs) are involved in the process of central nervous system neurodegeneration. Here, we report that mir-145, a miRNA enriched in rat spinal neurons and astrocytes, was downregulated at 1 week and 1 month after SCI. Our in vitro studies using astrocytes prepared from neonatal spinal cord tissues indicated that potent inflammagen lipopolysaccharide downregulated mir-145 expression in astrocytes, suggesting that SCI-triggered inflammatory signaling pathways could play the inhibitory role in astrocytic mir-145 expression. To induce overexpression of mir-145 in astrocytes at the spinal cord lesion site, we developed a lentivirus-mediated pre-miRNA delivery system using the promoter of glial fibrillary acidic protein (GFAP), an astrocyte-specific intermediate filament. The results indicated that astrocyte-specific overexpression of mir-145 reduced astrocytic cell density at the lesion border of the injured spinal cord. In parallel, overexpression of mir-145 reduced the size of astrocytes and the number of related cell processes, as well as cell proliferation and migration. Through a luciferase reporter system, we found that GFAP and c-myc were the two potential targets of mir-145 in astrocytes. Together, the findings demonstrate the novel role of mir-145 in the regulation of astrocytic dynamics, and reveal that the downregulation of mir-145 in astrocytes is a critical factor inducing astrogliosis after SCI. GLIA 2015;63:194-205.

Keywords: astrocytes; astrogliosis; inflammation; microRNA; mir-145; spinal cord injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Astrocytes / drug effects
  • Astrocytes / metabolism
  • Cell Movement / drug effects
  • Cell Movement / genetics
  • Cells, Cultured
  • Cytokines / pharmacology
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Female
  • Gene Expression Regulation / physiology
  • Glial Fibrillary Acidic Protein / metabolism
  • Gliosis / etiology*
  • Gliosis / therapy*
  • Gray Matter / metabolism
  • Gray Matter / pathology
  • Lipopolysaccharides / pharmacology
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • MicroRNAs / therapeutic use*
  • Neurons / drug effects
  • Neurons / metabolism
  • Phosphopyruvate Hydratase / metabolism
  • Proto-Oncogene Proteins c-myc / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects
  • Spinal Cord Injuries / complications*
  • Spinal Cord Injuries / pathology
  • Spinal Cord Injuries / therapy

Substances

  • Cytokines
  • Enzyme Inhibitors
  • Glial Fibrillary Acidic Protein
  • Lipopolysaccharides
  • MIRN145 microRNA, rat
  • MicroRNAs
  • Proto-Oncogene Proteins c-myc
  • Phosphopyruvate Hydratase